Clinical Assessment: Anterior STEMI with Post-Thrombolysis ST Resolution

What Has Happened So Far

• Pain has significantly reduced
• ST elevation is subsiding

Is Another Dose of Thrombolysis Needed?

What Should Be Done Next: Pharmaco-Invasive Strategy

Step-by-step next management:

1. Confirm reperfusion success at 60-90 minutes post-fibrinolysis:
   • ST resolution >50% on repeat ECG
   • Pain relief
   • Watch for reperfusion arrhythmia (benign AIVR is a good sign; VF needs management)
2. Continue antithrombotic therapy:
   • Dual antiplatelet therapy (aspirin + clopidogrel/ticagrelor - note ticagrelor and prasugrel are generally preferred post-PCI, but if tenecteplase was used in a younger patient, clopidogrel is often used as the loading P2Y12 inhibitor with fibrinolytics per current protocols)
   • Anticoagulation (heparin or LMWH/enoxaparin, depending on the fibrinolytic used and local protocol)
3. Transfer to PCI-capable centre within 2-24 hours for coronary angiography and likely PCI of the culprit LAD lesion. The 2024 SCAI consensus statement reaffirms this pharmaco-invasive approach for STEMI patients treated with fibrinolytics.
4. If ST elevation does NOT resolve by >50% at 90 minutes - that changes the picture entirely: the patient needs rescue PCI immediately (urgent transfer + angiography as fast as possible).
5. Monitoring in the interim:
   • Continuous cardiac monitoring (high risk of arrhythmia in first 24-48 hours)
   • Serial ECGs every 30-60 minutes
   • Serial troponin (I or T) - peak timing helps estimate infarct size
   • Echo to assess LV function (EF, wall motion abnormalities)
   • Blood pressure monitoring, oxygen saturation

Why This Patient Needs PCI Despite Successful Thrombolysis

Risk Stratification in This Patient

• Premature coronary artery disease - lipid panel, Lp(a), homocysteine
• Spontaneous coronary artery dissection (SCAD) - though more common in women, possible in young males
• Coronary vasospasm (Prinzmetal variant) - though the anterior ST elevation with radiation pattern suggests true STEMI
• Thrombophilia if no obstructive lesion is found at angiography (MINOCA workup)

Summary Decision Tree

ST elevation subsiding + pain relieved after thrombolysis
       ↓
Successful reperfusion confirmed (>50% ST resolution at 90 min)
       ↓
Do NOT repeat thrombolysis
       ↓
Start/continue DAPT + anticoagulation
       ↓
Transfer to PCI centre → Coronary angiography within 2-24 hours
       ↓
PCI of culprit LAD lesion (pharmaco-invasive strategy)

Key References

• PMC: STEMI Management in Different Settings - comprehensive review of AHA/ESC guideline recommendations
• ANZCOR Reperfusion Strategy Guideline - pharmaco-invasive strategy recommendation
• SCAI 2024 Expert Consensus on Primary PCI in STEMI - current best practice

Clinical Management: 33F with Acute + Recurrent Cholecystitis, Normal Coagulation

Step 1: Interpret the Coagulation Profile First

• No coagulopathy is present
• No anticoagulant effect detected
• The patient's clotting cascade (both extrinsic/PT and intrinsic/APTT pathways) is intact
• Liver synthetic function is adequate (PT/INR are liver-derived factors)

Step 2: Severity Grading (Tokyo Guidelines 2018)

• Bailey & Love's Short Practice of Surgery, 28th Ed., Table 71.2
• Sabiston Textbook of Surgery, p. 1831

Step 3: The Primary Management Decision - Surgery

1. Acute cholecystitis (current episode)
2. Recurrent history of cholecystitis - this alone is a strong independent indication for surgery
3. Normal coagulation - no surgical bleeding risk from a haemostasis standpoint
4. Young age (33 years), no significant comorbidities mentioned

"For patients with symptomatic gallstones, cholecystectomy is the treatment of choice if there are no medical contraindications."

• Bailey & Love's Short Practice of Surgery, 28th Edition, p. 1266

"Currently, the preferred treatment plan is to perform laparoscopic cholecystectomy in all patients after an episode of acute cholecystitis unless there are specific contraindications."

• Swanson's Family Medicine Review

Step 4: Timing of Cholecystectomy

• This is now the gold standard recommended by Tokyo Guidelines 2018, WSES 2016, SAGES, and the 2024 ACS review
• Shorter total hospital stay
• Avoids the risk of recurrence during the "waiting period" (approximately 20% of patients managed conservatively fail before planned interval surgery)
• No increased conversion rate or bile duct injury compared to delayed surgery
• A 2024 systematic review (PMID: 39607476) confirmed that even beyond the 7-day mark, early cholecystectomy for acute cholecystitis remains safe

• Reserved for patients presenting late in the disease process (>72-96 hours from symptom onset with "cooling down"), or with optimisable comorbidities
• If the acute episode has already resolved and the patient is stable, waiting 6 weeks and performing elective laparoscopic cholecystectomy is also acceptable

Step 5: Immediate Pre-Operative Management

1. Nil by mouth - standard pre-operatively
2. IV fluids - resuscitate and maintain hydration
3. IV broad-spectrum antibiotics - targeting common biliary organisms (E. coli, Klebsiella, Enterobacter, Bacteroides):
   • Cefazolin or cefuroxime (first/second generation cephalosporin) OR
   • Piperacillin-tazobactam for moderate-severe cases
4. Analgesics - IV paracetamol and/or NSAIDs; opioids if needed (morphine or tramadol)
5. Investigations to complete before surgery:
   • USG abdomen (confirm acute cholecystitis, assess GB wall, pericholecystic fluid, stones, CBD diameter)
   • LFTs, serum bilirubin, ALP - if elevated, suspect choledocholithiasis; perform MRCP to exclude CBD stones before or at time of surgery
   • CBC, renal function, blood glucose, group & crossmatch
   • Chest X-ray, ECG (routine pre-operative)
6. If jaundice or elevated bilirubin/ALP is present: MRCP mandatory to rule out choledocholithiasis or Mirizzi syndrome before proceeding to cholecystectomy

Step 6: Intraoperative Considerations

• Laparoscopic cholecystectomy is the approach of choice
• Intraoperative cholangiography or ICG (indocyanine green) fluorescence cholangiography is recommended - especially valuable in acute/recurrent cholecystitis where anatomy may be distorted
• Critical view of safety must be achieved before clipping the cystic duct and artery
• Conversion to open cholecystectomy is acceptable if anatomy is unclear (conversion rate in acute cholecystitis is 6-35%)
• If the gallbladder is gangrenous or severely inflamed and anatomy is obscured, bail-out procedures (subtotal cholecystectomy, cholecystostomy) are options

Step 7: Post-Operative Care

• Continue antibiotics if Grade II/III; single-dose prophylaxis sufficient for Grade I
• DVT prophylaxis (LMWH + compression stockings) - important even in young women
• Early mobilisation
• If surgery was for acute episode: follow up in 4-6 weeks with repeat imaging/LFTs
• Histopathology of the gallbladder specimen is routine (to exclude rare gallbladder malignancy)

Summary Decision Flow

33F, Recurrent + Acute Cholecystitis
         ↓
Coagulation: PT 11.5, INR 0.9, APTT 34.6 → ALL NORMAL
         ↓
No coagulopathy, no surgical bleeding risk from coagulation standpoint
         ↓
Tokyo Grade: Likely Grade I-II (no organ dysfunction, INR <1.5)
         ↓
Immediate management: NBM, IV fluids, IV antibiotics, analgesia
         ↓
Investigations: USG confirmed, CBC/LFTs/RFTs, MRCP if jaundice/elevated bilirubin
         ↓
DEFINITIVE TREATMENT: Early Laparoscopic Cholecystectomy
(within 72 hours-7 days of symptom onset, same admission)
         ↓
ICG/intraoperative cholangiography for safe anatomy identification
         ↓
Post-op: continue antibiotics, DVT prophylaxis, histopathology